Navigation Links
OncoSec Receives ISO 13485 Quality Management System Certification
Date:7/30/2012

the OMS has been used in Europe in Phase IV clinical trials for the treatment of head and neck cancer and cutaneous and subcutaneous skin cancers.

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec Announces Issuance of New Patent for Method of Use
2. OncoSec Closes $7.75 Million Public Offering
3. OncoSec to Present at 10th Annual BioPartnering North America
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. UCSB assistant professor of physics receives US Presidential Science Award
6. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
7. RIT professor receives National Science Foundation grant to improve on-chip networks with wireless technology
8. Little known pregnancy disease, Hyperemesis Gravidarum, receives awareness with a $20,000 donation from the H.E.R. Foundation to begin Genome Research at UCLA
9. Lupin Receives FDA Approval for Generic LYRICA(R)
10. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
11. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... Supplies - Global Strategic Business Report" report to their offering. ... and Tissue Culture Supplies in US$ Thousands by the following Product ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . Annual ...
(Date:8/19/2014)... Robin Williams’ passing is a sad reminder ... individual. Symptoms range from slowness of voluntary movements ... severe depression. Parkinson’s disease progressively gets worse over ... neurons of the brain. As these patients struggle ... progressively gets worse, they look for options. ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated ... in a new PSUR – responding to the increasing need ... a drug. Adopted in many regions, the main objectives of ... comprehensive and critical analysis of new or emerging information on ... new evidence of the potential benefits of a drug; and ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... a new platform-independent Java client API for exchanging files ... HTTPS encrypted connections. , ,MOVEit API Java will supplement ... Windows API and a Perl API for Unix systems, ... ,The Java offering is targeted at mainframe, Solaris, Linux ...
... There are three locations on an Internet search page: top, ... a single page and other times its 100 feet long. ... sites identity is successful, only then will it will float ... if its submerged like a submarine, it will stay caught ...
... put his Ph.D. in theoretical physics to use not in ... affairs officer for the National Science Foundation . , ... residence for the week, he presented a public lecture ... Weapon, at which he discussed the relationship between writing science ...
Cached Biology Technology:Does your web site have visibility? 2Does your web site have visibility? 3NSF officer speaks on the future of journalism and science 2NSF officer speaks on the future of journalism and science 3
(Date:8/19/2014)... many parts of the world, leprosy and tuberculosis ... cases of leprosy per year, with nearly all ... currently available century-old vaccine Bacille Calmette-Guerin, or BCG, ... leprosy, so a more potent vaccine is needed ... found a stronger weapon against both diseases., In ...
(Date:8/19/2014)... (Boston) Some infants born with neonatal abstinence ... a more difficult time going through withdrawal than ... understood. While genetic and epigenetic (when genes are ... identified as potential factors, researchers at Boston University ... (BMC) conducted a first of its kind study ...
(Date:8/19/2014)... University of Texas Health Science Center at San Antonio ... today announced the awarding of more than $750,000 in ... Innovation Challenge. , Launched in 2003, SALSI is a ... an academic health science center join forces for greater ... collaborative studies, with a focus on public health issues ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... of developing bipolar disorder depends in part on the combined, ... the brain, none of which is powerful enough to cause ... targeting the enzyme produced by one of these genes could ... research was conducted by scientists at the National Institutes of ...
... studied the molecular basis of memory storage, trying to ... stores genetic memory. In an important study published this ... report for the first time that memory storage can ... rat hippocampus by manipulating a so-called "memory molecule," a ...
... for their effects on fat development, researchers have discovered ... in mice without some of the side effects attributed ... as harmine, was first isolated more than 150 years ... preparations around the world, the team reports in the ...
Cached Biology News:Genetic roots of bipolar disorder revealed by first genome-wide study of illness 2Genetic roots of bipolar disorder revealed by first genome-wide study of illness 3New Brandeis research sheds light on memory by erasing it 2Fat screen delivers plant-derived chemical with antidiabetic effects 2
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biology Products: